试验注册
在健康成人中评估 MK-4208/TERN-701 的临床试验（MK-4208-001/TERN701-1014）
A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014)
作者：Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
ClinicalTrials.gov · 2026年9月24日 · Terns, Inc., a subsidiary of Merck & Co…
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要）…
已等待 0 秒大约需要 10–20 秒
可以先看别的，做好了会自动出现在这里。
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要一两分钟。
摘要Abstract
Brief summary: The goal of the study is to learn what happens to different doses and forms of TERN-701 in a healthy person's body over time. Researchers will compare what happens to different doses and forms of TERN-701 in a person's body over time when given with or without food, or with or without other medications. The goal of the study is to learn: * What happens to different doses of TERN-701 in a person's body over time when it is given with or without food, or with or without other medications. * About the safety of TERN-701 and if people tolerate it
Conditions: Healthy
Interventions: drug: TERN-701 (MK-4208, HS-10382); drug: Rabeprazole; drug: Midazolam; drug: Digoxin; drug: Pravastatin; drug: Montelukast; drug: Omeprazole; drug: Itraconazole; drug: Warfarin; drug: Rosuvastatin; drug: Bosentan; drug: Quinidine
Phase: Phase 1
Enrollment: 196 (actual)
Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (industry)
Countries: United States
Status: completed
还没有查过关联研究
我会去找这篇研究之前的基础工作、做类似事情的研究，以及之后引用它的研究，并说明每篇为什么相关。